Physician profile
Dalia Fulop
NPI 1578589198
$18,328.56
in general payments reported to CMS, 2019-2025
65 companies · $3,001 in 2025
The $3,001 reported for 2025 was more than what 88% of Diagnostic Neuroimaging (Psychiatry & Neurology) providers received nationally (typical 2025 total: $1,744).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,083 · 2020: $1,237 · 2021: $2,146 · 2022: $2,680 · 2023: $3,166 · 2024: $4,016 · 2025: $3,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,007.88 |
| Education | $174.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,118.82 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,715.99 | 2019-2025 | |
| Biogen, INC. | $941.29 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Ucb, INC. | $846.28 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Mdd US Operations, LLC | $804.30 | 2019-2025 | Gocovri, Gocovri |
| Argenx US, INC. | $791.93 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Csl Behring | $725.10 | 2019-2025 | Hizentra |
| Pfizer INC. | $694.57 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $567.09 | 2021-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $546.46 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $507.82 | 2019-2025 | Ultomiris |
| Lilly USA, LLC | $487.09 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Emd Serono, INC. | $460.87 | 2019-2025 | Mavenclad |
| Genzyme Corporation | $456.03 | 2019-2023 | |
| Sk Life Science, INC. | $454.06 | 2020-2025 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dalia Fulop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.